RxDoctor Payments Data

Laura Jernigan

Family · Gainesville, GANPI 1184220402

Payments from drug & device makers

$10,098in general payments, 2019–2025

Across 410 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$789
  • UCB, Inc.$767
  • Neurocrine Biosciences, Inc.$461
  • Argenx US, Inc.$451
  • Jazz Pharmaceuticals Inc.$415
  • plus $6K from 43 others

What the payments were for

  • Travel & lodging$8248%
  • Food & beverage$9,05090%
  • Education$2242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,098 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$19,627
Medicare patients
207
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate20$30,413
QuliptaAtogepant15$16,071
NamzaricMemantine Hcl/Donepezil Hcl18$15,609
Aimovig AutoinjectorErenumab-Aooe13$14,707
SunosiSolriamfetol Hcl11$9,335
Memantine Hcl ErMemantine Hcl17$3,977
Gabapentin168$2,376
Memantine Hcl107$2,170
Donepezil Hcl189$1,648
Levetiracetam38$1,526
Eszopiclone29$1,309
Pregabalin37$1,147
Carbidopa-LevodopaCarbidopa/Levodopa36$1,074
RizatriptanRizatriptan Benzoate33$758
Quetiapine Fumarate36$699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Namzaric$789$31,67933 claims
PfizerNurtec Odt$402$30,41320 claims
Axsome Therapeutics, Inc.Sunosi$173$9,33511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →